Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2008

01-05-2008 | Epidemiology

The impact of diabetes on survival following breast cancer

Authors: Lorraine L. Lipscombe, Pamela J. Goodwin, Bernard Zinman, John R. McLaughlin, Janet E. Hux

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

Purpose It has been suggested that type 2 diabetes may affect breast cancer prognosis, possibly due to increased diabetes-related comorbidity, or direct effects of insulin resistance and/or hyperinsulinemia. The purpose of this study was to examine the impact of diabetes on survival following breast cancer. Methods Using population-based health databases from Ontario, Canada, this retrospective cohort study compared deaths between women with breast cancer aged 55–79 years with diabetes and without diabetes. Women were followed for all cause mortality from breast cancer diagnosis until March 31st 2006. Results Of the 6,107 women with breast cancer, 1,011 had diabetes and 5,096 did not have diabetes. Women with diabetes were slightly older, were more likely to reside in a lower income neighborhood, and had greater comorbidity compared to women without diabetes. After a mean follow-up of 5.0 years and adjustment for age, prior mammograms and other covariates, mortality following breast cancer was significantly higher among women with versus without diabetes (hazard ratio, HR 1.39, 95% confidence interval, CI 1.22–1.59, P < 0.0001). The effect of diabetes on mortality was comparable to that seen in women with diabetes without breast cancer over a 7-year follow-up. Conclusion This study found that diabetes was associated with a close to 40% increase in mortality within the first 5 years following breast cancer, which was similar to that seen in women with diabetes without breast cancer. These findings suggest that early survival following breast cancer is reduced in women with diabetes, possibly due to diabetes-related causes.
Literature
1.
go back to reference Lipscombe LL, Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet 369(9563):750–756PubMedCrossRef Lipscombe LL, Hux JE (2007) Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet 369(9563):750–756PubMedCrossRef
2.
go back to reference American Cancer Society (2005) Cancer facts and figures 2005. American Cancer Society, Atlanta American Cancer Society (2005) Cancer facts and figures 2005. American Cancer Society, Atlanta
3.
go back to reference Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA et al (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 26(6):1752–1758PubMedCrossRef Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA et al (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 26(6):1752–1758PubMedCrossRef
4.
go back to reference Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156(4):349–352PubMedCrossRef Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156(4):349–352PubMedCrossRef
5.
go back to reference Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71(3):360–363PubMedCrossRef Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71(3):360–363PubMedCrossRef
6.
go back to reference Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 98(3):349–356PubMedCrossRef Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 98(3):349–356PubMedCrossRef
7.
go back to reference Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2):194–202PubMedCrossRef Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2):194–202PubMedCrossRef
8.
go back to reference Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89(18):1360–1365PubMedCrossRef Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89(18):1360–1365PubMedCrossRef
9.
go back to reference Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51PubMedCrossRef Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51PubMedCrossRef
10.
go back to reference Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van PC, Dunn BP et al (2003) Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol 158(10):963–968PubMedCrossRef Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van PC, Dunn BP et al (2003) Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol 158(10):963–968PubMedCrossRef
11.
go back to reference Pasanisi P, Berrino F, De PM, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238PubMedCrossRef Pasanisi P, Berrino F, De PM, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238PubMedCrossRef
12.
go back to reference Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciacca L et al (1996) Insulin receptors in breast cancer. Ann N Y Acad Sci 784:173–188PubMedCrossRef Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciacca L et al (1996) Insulin receptors in breast cancer. Ann N Y Acad Sci 784:173–188PubMedCrossRef
13.
go back to reference Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109(6):565–571PubMed Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109(6):565–571PubMed
14.
go back to reference Papa V, Belfiore A (1996) Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19(5):324–333PubMed Papa V, Belfiore A (1996) Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19(5):324–333PubMed
15.
go back to reference Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159(12):1160–1167PubMedCrossRef Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159(12):1160–1167PubMedCrossRef
16.
go back to reference Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from verona. Diabetes Care26(4):1047–1051 Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from verona. Diabetes Care26(4):1047–1051
17.
go back to reference Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41(5):779–785 Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41(5):779–785
18.
go back to reference Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older JAMA 285(7):885–892PubMedCrossRef Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older JAMA 285(7):885–892PubMedCrossRef
19.
go back to reference Robles SC, Marrett LD, Clarke EA, Risch HA (1988) An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41(5):495–501PubMedCrossRef Robles SC, Marrett LD, Clarke EA, Risch HA (1988) An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41(5):495–501PubMedCrossRef
20.
go back to reference McLaughin JR, Sloan MR, Janovjak DP (1995). Cancer survival in Ontario. The Ontario Cancer Treatment and Research Foundation1–9 McLaughin JR, Sloan MR, Janovjak DP (1995). Cancer survival in Ontario. The Ontario Cancer Treatment and Research Foundation1–9
21.
go back to reference Hux JE, Ivis F, Flintoft V, Bica A (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25(3):512–516PubMedCrossRef Hux JE, Ivis F, Flintoft V, Bica A (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25(3):512–516PubMedCrossRef
22.
go back to reference American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28(suppl_1):S37–S42CrossRef American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28(suppl_1):S37–S42CrossRef
23.
go back to reference Weiner JP, Starfield BH, Steinwachs DM, Mumford LM (1991) Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 29(5):452–472PubMedCrossRef Weiner JP, Starfield BH, Steinwachs DM, Mumford LM (1991) Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 29(5):452–472PubMedCrossRef
24.
go back to reference Lipscombe LL, Hux JE, Booth GL (2005) Reduced screening mammography among women with diabetes. Arch Intern Med 165(18):2090–2095PubMedCrossRef Lipscombe LL, Hux JE, Booth GL (2005) Reduced screening mammography among women with diabetes. Arch Intern Med 165(18):2090–2095PubMedCrossRef
25.
go back to reference Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL (1995)Efficacy of screening mammography. A meta-analysis. JAMA 273(2):149–154 Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL (1995)Efficacy of screening mammography. A meta-analysis. JAMA 273(2):149–154
26.
go back to reference Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158(9):915–920PubMedCrossRef Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158(9):915–920PubMedCrossRef
27.
go back to reference Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16(9):3115–3120PubMed Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16(9):3115–3120PubMed
Metadata
Title
The impact of diabetes on survival following breast cancer
Authors
Lorraine L. Lipscombe
Pamela J. Goodwin
Bernard Zinman
John R. McLaughlin
Janet E. Hux
Publication date
01-05-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9654-0

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine